LY01616
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LY01616, covering 2024-04-25 to 2024-04-25. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]